319 related articles for article (PubMed ID: 14579523)
21. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
Väänänen K
Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Marx RE; Sawatari Y; Fortin M; Broumand V
J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
[TBL] [Abstract][Full Text] [Related]
23. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis I; Kousidou OCh; Karamanos NK
In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
[TBL] [Abstract][Full Text] [Related]
25. Development of Src tyrosine kinase substrate binding site inhibitors.
Ye G; Tiwari R; Parang K
Curr Opin Investig Drugs; 2008 Jun; 9(6):605-13. PubMed ID: 18516760
[TBL] [Abstract][Full Text] [Related]
26. [Bisphosphonates: the molecular targets and mechanisms of action].
Wada S; Kamiya S; Ono K
Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
28. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
Palanki MS; Akiyama H; Campochiaro P; Cao J; Chow CP; Dellamary L; Doukas J; Fine R; Gritzen C; Hood JD; Hu S; Kachi S; Kang X; Klebansky B; Kousba A; Lohse D; Mak CC; Martin M; McPherson A; Pathak VP; Renick J; Soll R; Umeda N; Yee S; Yokoi K; Zeng B; Zhu H; Noronha G
J Med Chem; 2008 Mar; 51(6):1546-59. PubMed ID: 18311895
[TBL] [Abstract][Full Text] [Related]
29. [Current topics in drug therapy aiming at bone resorption].
Yasui T; Tanaka S
Clin Calcium; 2006 Sep; 16(9):1475-79. PubMed ID: 16951471
[TBL] [Abstract][Full Text] [Related]
30. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
31. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
Plotkin LI; Manolagas SC; Bellido T
Bone; 2006 Sep; 39(3):443-52. PubMed ID: 16627025
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon FP; Thompson K; Rogers MJ
Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of action of bisphosphonates.
Rodan GA
Annu Rev Pharmacol Toxicol; 1998; 38():375-88. PubMed ID: 9597160
[TBL] [Abstract][Full Text] [Related]
34. The relative contribution of cysteine proteinases and matrix metalloproteinases to the resorption process in osteoclasts derived from long bone and scapula.
Shorey S; Heersche JN; Manolson MF
Bone; 2004 Oct; 35(4):909-17. PubMed ID: 15454098
[TBL] [Abstract][Full Text] [Related]
35. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Miki T; Minamide T
Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
[TBL] [Abstract][Full Text] [Related]
36. Benzodiazepine compounds as inhibitors of the src protein tyrosine kinase: screening of a combinatorial library of 1,4-benzodiazepines.
Ramdas L; Bunnin BA; Plunkett MJ; Sun G; Ellman J; Gallick G; Budde RJ
Arch Biochem Biophys; 1999 Aug; 368(2):394-400. PubMed ID: 10441393
[TBL] [Abstract][Full Text] [Related]
37. Activation of Src kinase by protein-tyrosine phosphatase-PEST in osteoclasts: comparative analysis of the effects of bisphosphonate and protein-tyrosine phosphatase inhibitor on Src activation in vitro.
Chellaiah MA; Schaller MD
J Cell Physiol; 2009 Aug; 220(2):382-93. PubMed ID: 19350555
[TBL] [Abstract][Full Text] [Related]
38. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of novel bisphosphonates with dual activities on bone in vitro.
Xie Y; Ding H; Qian L; Yan X; Yang C; Xie Y
Bioorg Med Chem Lett; 2005 Jul; 15(13):3267-70. PubMed ID: 15936189
[TBL] [Abstract][Full Text] [Related]
40. Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.
Barchéchath S; Williams C; Saade K; Lauwagie S; Jean-Claude B
Chem Biol Drug Des; 2009 Apr; 73(4):380-7. PubMed ID: 19291100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]